此前连续大跌的启明医疗-B(2500.HK) 今日反弹逾 5%,报 47.45 港元,暂成交 5624 万港元,总市值 210 亿港元。华创证券日前表示,维持启明医疗-B“推荐” 评级,目标价 105 港元,较目前价位有翻倍空间。该行指,今年上半年,公司 TAVR 手术终端植入量约为 1900 台 (包含部分捐赠性质植入),较去年同期约 700 台终端植入量增长迅速。脑保护器装置 Tri GUARD3 海外收入亦大幅提升。另外,公司委任 Martin B. Leon 教授担任 RDN 创新器械全球首要研究者,在 RDN 领域,Martin 教授及其团队已担任多个创新器械的临床试验 PI。
券商高呼 “股价有翻倍空间”,启明医疗-B 盘中大涨逾 5%
Source: 格隆汇 The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment